The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Adoptive Transfer of Epstein-Barr Virus (EBV) Nuclear Antigen 1–Specific T Cells As Treatment for EBV Reactivation and Lymphoproliferative Disorders After Allogeneic Stem-Cell Transplantation
Open accessAbstract
Purpose: Reactivation of Epstein-Barr virus (EBV) after allogeneic stem-cell transplantation (SCT) can lead to severe life-threatening infections and trigger post-transplantation lymphoproliferative disease (PTLD). Since EBV-specific T cells could prevent PTLD, cellular immunotherapy has been a promising treatment option. However, generation of antigen-specific T-cell populations has been difficult within a short time frame. Patients and Methods: To improve availability in urgent clinical conditions, we developed a rapid protocol for isolation of polyclonal EBV nuclear antigen 1 (EBNA-1) –specific T cells by using an interferon gamma (IFN-γ) capture technique. Results: We report on the use of adoptive transfer of EBNA-1–specific T cells in 10 pediatric and adult patients with EBV viremia and/or PTLD after SCT. No acute toxicity or graft-versus-host disease (GVHD) of more than grade 2 occurred as a result of adoptive T-cell transfer. In vivo expansion of transferred EBNA-1–specific T cells was observed in eight of 10 patients after a median of 16 days following adoptive transfer that was associated with clinical and virologic response in seven of them (70%). None of the responders had EBV-associated mortality. Within clinical responders, three patients were disease free by the day of last follow-up (2 to 36 months), three patients died of other infectious complications, and one patient died as a result of relapse of malignancy. EBV-related mortality was observed in two of 10 patients, and another patient had ongoing viremia without clinical symptoms at last follow-up. Conclusion: Adoptive ex vivo transfer of EBNA-1–specific T cells is a feasible and well-tolerated therapeutic option, representing a fast and efficient procedure to achieve reconstitution of antiviral T-cell immunity after SCT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epstein–Barr virus: 40 years on
Young, L. S., & Rickinson, A. B. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1452 · Cited by 2,227
Restoration of Viral Immunity in Immunodeficient Humans by the Adoptive Transfer of T Cell Clones
Riddell, S. R., Watanabe, K. S., Goodrich, J. M., Li, C. R., Agha, M. E., & Greenberg, P. D. (1992) · Science · doi:10.1126/science.1352912 · Cited by 1,201
Rooney, C. M., Smith, C. A., Ng, C. Y. C., Loftin, S. K., Sixbey, J. W., Gan, Y., Srivastava, D.-K., Bowman, L. C., Krance, R. A., Brenner, M. K., et al. (1998) · Blood · doi:10.1182/blood.v92.5.1549 · Cited by 1,135
Gattinoni, L. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24480 · Cited by 958
Helping the CD8+ T-cell response
Bevan, M. J. (2004) · Nature Reviews Immunology · doi:10.1038/nri1413 · Cited by 797
Heslop, H. E., Slobod, K. S., Pule, M. A., Hale, G. A., Rousseau, A., Smith, C. A., Bollard, C. M., Liu, H., Wu, M.-F., Rochester, R. J., et al. (2010) · Blood · doi:10.1182/blood-2009-08-239186 · Cited by 780
Sun, J. C., Williams, M. A., & Bevan, M. J. (2004) · Nature Immunology · doi:10.1038/ni1105 · Cited by 649
Leen, A. M., Myers, G. D., Sili, U., Huls, M. H., Weiss, H., Leung, K. S., Carrum, G., Krance, R. A., Chang, C.-C., Molldrem, J. J., et al. (2006) · Nature Medicine · doi:10.1038/nm1475 · Cited by 545
Feuchtinger, T., Opherk, K., Bethge, W. A., Topp, M. S., Schuster, F. R., Weissinger, E. M., Mohty, M., Or, R., Maschan, M., Schumm, M., et al. (2010) · Blood · doi:10.1182/blood-2010-01-262089 · Cited by 435
Self-citationFeuchtinger, T., Matthes‐Martin, S., Richard, C., Lion, T., Fuhrer, M., Hamprecht, K., Handgretinger, R., Peters, C., Schuster, F. R., Beck, R., et al. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06108.x · Cited by 394
Self-citationvan Esser, J. W. J., van der Holt, B., Meijer, E., Niesters, H. G. M., Trenschel, R., Thijsen, S. F. T., van Loon, A. M., Frassoni, F., Bacigalupo, A., Schaefer, U. W., et al. (2001) · Blood · doi:10.1182/blood.v98.4.972 · Cited by 373
A Single Naive CD8+ T Cell Precursor Can Develop into Diverse Effector and Memory Subsets
Stemberger, C., Huster, K. M., Koffler, M., Anderl, F., Schiemann, M., Wagner, H., & Busch, D. H. (2007) · Immunity · doi:10.1016/j.immuni.2007.10.012 · Cited by 345
Gustafsson, A., Levitsky, V., Zou, J.-Z., Frisan, T., Dalianis, T., Ljungman, P., Ringden, O., Winiarski, J., Ernberg, I., & Masucci, M. G. (2000) · Blood · doi:10.1182/blood.v95.3.807.003k24_807_814 · Cited by 330
How I treat EBV lymphoproliferation
Heslop, H. E. (2009) · Blood · doi:10.1182/blood-2009-07-143545 · Cited by 304
Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells
Moosmann, A., Bigalke, I., Tischer, J., Schirrmann, L., Kasten, J., Tippmer, S., Leeping, M., Prevalšek, D., Jaeger, G., Ledderose, G., et al. (2010) · Blood · doi:10.1182/blood-2009-08-236356 · Cited by 221
Comoli, P., Basso, S., Zecca, M., Pagliara, D., Baldanti, F., Bernardo, M. E., Barberi, W., Moretta, A., Labirio, M., Paulli, M., et al. (2007) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2007.01823.x · Cited by 199
Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects
Melenhorst, J. J., Leen, A. M., Bollard, C. M., Quigley, M. F., Price, D. A., Rooney, C. M., Brenner, M. K., Barrett, A. J., & Heslop, H. E. (2010) · Blood · doi:10.1182/blood-2010-06-289991 · Cited by 192
Lewin, S. R., Heller, G., Zhang, L., Rodrigues, E., Skulsky, E., van den Brink, M. R. M., Small, T. N., Kernan, N. A., O'Reilly, R. J., Ho, D. D., et al. (2002) · Blood · doi:10.1182/blood.v100.6.2235 · Cited by 179
Immunodeficiency-associated lymphomas
Tran, H., Nourse, J., Hall, S., Green, M., Griffiths, L., & Gandhi, M. K. (2008) · Blood Reviews · doi:10.1016/j.blre.2008.03.009 · Cited by 172
Meij, P., van Esser, J. W. J., Niesters, H. G. M., van Baarle, D., Miedema, F. F., BLAKE, N. W., Rickinson, A. B., Leiner, I. M., Pamer, E. G., Löwenberg, B., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3001 · Cited by 142
Feuchtinger, T. F., Lang, P., Hamprecht, K., Schumm, M., Greil, J., Jahn, G., NIETHAMMER, D., & Einsele, H. (2004) · Experimental Hematology · doi:10.1016/j.exphem.2003.12.009 · Cited by 108
Self-citationMohty, M., Jacot, W., Faucher, C., Bay, J., Zandotti, C., Collet, L., Choufi, B., Bilger, K., Tournilhac, O., Vey, N., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2403105 · Cited by 103
Feuchtinger, T. F., Richard, C., Joachim, S., Scheible, M. H., Schumm, M., Hamprecht, K., Martin, D. D., Jahn, G., Handgretinger, R., & Lang, P. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31815ef862 · Cited by 96
Self-citationEBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT
Ocheni, S., Kroeger, N., Zabelina, T., Sobottka, I., Ayuk, F. A., Wolschke, C., Muth, A., Lellek, H., Petersen, L., Erttmann, R., et al. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.150 · Cited by 94
Meyer, V. S., Drews, O., Günder, M., Hennenlotter, J., Rammensee, H., & Stevanović, S. (2009) · Journal of Proteome Research · doi:10.1021/pr800937k · Cited by 63
Expansion of EBNA1-specific effector T cells in posttransplantation lymphoproliferative disorders.
Jones, K., Nourse, J., Morrison, L. E., Nguyen-Van, D., Moss, D., Burrows, S., & Gandhi, M. (2010) · Blood · doi:10.1182/blood-2010-03-274076 · Cited by 56
Bahceci, E., Epperson, D. E., Douek, D. C., Melenhorst, J. J., Childs, R., & Barrett, A. J. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04522.x · Cited by 47
O’Reilly, R. J., Doubrovina, E. S., Trivedi, D., Hasan, A. N., Kollen, W. J. W., & Koehne, G. (2007) · Immunologic Research · doi:10.1007/s12026-007-0059-2 · Cited by 47
Adoptive cell therapy against EBV-related malignancies: a survey of clinical results
Merlo, A., Turrini, R., Dolcetti, R., Zanovello, P., Amadori, A., & Rosato, A. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.9.1265 · Cited by 43
Dong, L., Gao, Z., Chang, L., et al. (2009) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0b013e3181bf5e2d · Cited by 32
Demachi‐Okamura, A., Ito, Y., Akatsuka, Y., Tsujimura, K., Morishima, Y., Takahashi, T., & Kuzushima, K. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00852.x · Cited by 30
Cited by
The Immunology of Epstein-Barr Virus–Induced Disease
Taylor, G. S., Long, H. M., Brooks, J. M., Rickinson, A. B., & Hislop, A. D. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112326 · Cited by 602
Bollard, C. M., Gottschalk, S., Torrano, V., Diouf, O., Ku, S., Hazrat, Y., Carrum, G., Ramos, C., Fayad, L., Shpall, E. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.5304 · Cited by 503
Tzannou, I., Papadopoulou, A., Naik, S., Leung, K., Martinez, C. A., Ramos, C. A., Carrum, G., Sasa, G., Lulla, P., Watanabe, A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.0655 · Cited by 457
Papadopoulou, A., Gerdemann, U., Katari, U. L., Tzannou, I., Liu, H., Martinez, C., Leung, K., Carrum, G., Gee, A. P., Vera, J. F., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008825 · Cited by 402
Virus-Specific T Cells for the Immunocompromised Patient
Houghtelin, A., & Bollard, C. M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01272 · Cited by 90
Metadata
- Authors
- Icheva, V., Kayser, S., Wolff, D., Tuve, S., Kyzirakos, C., Bethge, W., Greil, J., Albert, M. H., Schwinger, W., Nathrath, M., Schumm, M., Stevanovic, S., Handgretinger, R., Lang, P., & Feuchtinger, T.
- Venue
- Journal of Clinical Oncology
- Published
- 2013-01-01
- Volume
- 31
- Issue
- 1
- Pages
- 39-48
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2139450265
- Cited by
- 268
- References
- 31
- FWCI
- 10.65
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.